We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.15%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$843M
AUM Growth
+$92.2M
Cap. Flow
+$126M
Cap. Flow %
14.96%
Top 10 Hldgs %
33.86%
Holding
109
New
20
Increased
44
Reduced
26
Closed
18

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$21.4M
2
CVS icon
CVS Health
CVS
+$19M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.7M
4
RVTY icon
Revvity
RVTY
+$16.1M
5
UNH icon
UnitedHealth
UNH
+$15.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$27.5M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$20.3M
3
ABT icon
Abbott
ABT
+$20M
4
GILD icon
Gilead Sciences
GILD
+$16.1M
5
BSX icon
Boston Scientific
BSX
+$11.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
1
Insulet
PODD
$9.79B
$34.3M 4.07%
130,514
+4,753
+4% +$1.29M
CVS icon
2
CVS Health
CVS
$122B
$33.7M 3.99%
496,736
+316,736
+176% +$19M
LLY icon
3
Eli Lilly
LLY
$1.06T
$32.4M 3.84%
39,191
+11,028
+39% +$9.18M
SYK icon
4
Stryker
SYK
$130B
$28.9M 3.43%
77,690
-27
-0% -$10.3K
THC icon
5
Tenet Healthcare
THC
$21.1B
$28.7M 3.4%
213,418
+106,431
+99% +$14M
BDX icon
6
Becton Dickinson
BDX
$48.2B
$27.6M 3.27%
120,283
+49,879
+71% +$11.6M
COO icon
7
Cooper Companies
COO
$14.5B
$26.4M 3.13%
312,650
+38,081
+14% +$3.41M
UNH icon
8
UnitedHealth
UNH
$370B
$26.3M 3.12%
50,213
+30,213
+151% +$15.4M
GILD icon
9
Gilead Sciences
GILD
$165B
$24.5M 2.91%
218,950
-155,875
-42% -$16.1M
BSX icon
10
Boston Scientific
BSX
$71.5B
$22.8M 2.7%
225,990
-111,364
-33% -$11.2M
ZBH icon
11
Zimmer Biomet
ZBH
$18.4B
$22.7M 2.69%
+200,500
New +$21.4M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$12.4B
$19.6M 2.32%
+277,252
New +$18.7M
NBIX icon
13
Neurocrine Biosciences
NBIX
$16.6B
$18.6M 2.21%
168,382
+52,655
+45% +$6.67M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$29.3B
$18.6M 2.21%
68,938
+30,266
+78% +$7.78M
TVTX icon
15
Travere Therapeutics
TVTX
$5.78B
$17.1M 2.03%
954,071
-163,721
-15% -$3.32M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$5.93B
$16.9M 2.01%
762,621
-2,832
-0.4% -$58.3K
VRNA
17
DELISTED
Verona Pharma
VRNA
$16.5M 1.96%
260,421
-460,236
-64% -$27.5M
RXST icon
18
RxSight
RXST
$260M
$15.9M 1.89%
631,238
+330,540
+110% +$9.82M
CVRX icon
19
CVRx
CVRX
$63.4M
$15M 1.78%
1,229,522
+308,348
+33% +$4.35M
MCK icon
20
McKesson
MCK
$101B
$14.9M 1.76%
22,101
-899
-4% -$556K
RVTY icon
21
Revvity
RVTY
$12.8B
$14.8M 1.75%
+139,557
New +$16.1M
EW icon
22
Edwards Lifesciences
EW
$51.7B
$14.6M 1.73%
200,819
+55,605
+38% +$3.98M
QGEN icon
23
Qiagen
QGEN
$8.72B
$14.4M 1.71%
359,644
+90,074
+33% +$3.79M
VRDN icon
24
Viridian Therapeutics
VRDN
$2.67B
$14.3M 1.7%
1,064,506
-23,128
-2% -$394K
PTCT icon
25
PTC Therapeutics
PTCT
$6.12B
$14.3M 1.69%
280,314
+102,946
+58% +$5.14M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Parkman Healthcare Partners held 109 positions worth $843M, up 12% from $751M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Parkman Healthcare Partners deployed $126M of net new capital in Q1 2025, opening 20 new positions and adding to 44 existing holdings. Its largest new stake was Zimmer Biomet: 200,500 shares worth $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $27.5M trimmed.

  • Parkman Healthcare Partners's largest Q1 2025 buy was Zimmer Biomet: 200,500 shares worth $22.7M.
  • Parkman Healthcare Partners added most to CVS Health in Q1 2025, an estimated $19M increase.
  • Parkman Healthcare Partners's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $27.5M.
  • Parkman Healthcare Partners fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $20.3M.
  • Parkman Healthcare Partners's ten largest holdings make up 34% of its $843M portfolio in Q1 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 18 in Q1 2025.
  • Parkman Healthcare Partners's portfolio value rose 12% quarter-over-quarter to $843M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.